The Immunotherapy Revolution: Towards Future Cancer Treatments
The discovery and development of immune checkpoint inhibitors has revolutionized the treatment of certain cancers, with the 2018 Nobel Prize in medicine/physiology recognizing these therapies as a "landmark in our fight against cancer." Yet, despite these advances, putative biomarker identification, efficacy, and drug resistance still pose significant therapeutic challenges. In this webinar, leaders in immuno-oncology — Elaine Mardis (The Ohio State University) and Jedd Wolchok (Memorial Sloan Kettering Cancer Center) — survey the landscape of research, revealing new approaches for harnessing the potential of this transformative therapeutic.
Co-Executive Director, Institute for Genomic Medicine at Nationwide Children's Hospital Professor of Pediatrics, The Ohio State University College of Medicine
Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation
Chief, Melanoma and Immunotherapeutics Service
Director, Parker Institute for Cancer Immunotherapy at MSK